Back to results

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Objective

To register, allocate, and assign patients to ComboMATCH Treatment Trials. Secondary Objectives To evaluate the rate of positive outcomes in defined cohorts within treatment trials of treatment combinations including targeted therapies for molecularly defined populations, and also in the subset of treatment trials where the treatments are supported by in vivo models. To perform quality control of the patients registered in the form of pathological confirmation of disease and sub-type to confirm diagnosis and treatment arm allocation.

Protocol #

EAY191

Trial Phase:

Phase II

Principal Investigator:

Poklepovic, Andrew

Cancer Type
  • Anus
  • Bones and Joints
  • Brain and Nervous System
  • Breast
  • Cervix
  • Colon
  • Corpus Uteri
  • Esophagus
  • Eye and Orbit
  • Kaposi's Sarcoma
  • Kidney
  • Larynx
  • Lip
  • Oral Cavity and Pharynx
  • Liver
  • Lung
  • Melanoma
  • Skin
  • Other Digestive Organ
  • Other Endocrine System
  • Other Female Genital
  • Other Male Genital
  • Other Respiratory and Intrathoracic Organs
  • Other Skin
  • Other Urinary
  • Ovary
  • Pancreas
  • Prostate
  • Rectum
  • Small Intestine
  • Soft Tissue
  • Stomach
  • Thyroid
  • Urinary Bladder
Study Site
  • Stony Point
  • Virginia Commonwealth University

Patient must have measurable disease
Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider.
All patients must have sequencing results available from an NCI credentialed Designated Laboratory (DL).
Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria:
Patients must have progressed on at least one line of standard systemic therapy OR
Patients whose disease has no standard treatment that has been shown to prolong overall survival.
Patients 18 years and older who have tumor amenable to minimal risk image-guided or direct vision biopsy and must be willing and able to undergo a tumor biopsy to obtain samples for research if the patient is to enroll in a ComboMATCH treatment trial. OR Patients 18 years and older who do not have disease that is biopsiable at minimal risk to the patient must confirm availability of an archival tumor tissue specimen for submission for research if the patient enrolls to a ComboMATCH Treatment Trial
Patients under 18 years old must confirm availability of an archival tumor tissue specimen for submission for research if patient enrolls to a ComboMATCH Treatment Trial.

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Both
  • Protocol Type Screening
  • Research Study Team Faith McFadden, MSN, RN
    Phone: +1 804-628-0616
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: